Candida haemulonii complex: species identification and antifungal susceptibility profiles of clinical isolates from Brazil.

@article{Ramos2015CandidaHC,
  title={Candida haemulonii complex: species identification and antifungal susceptibility profiles of clinical isolates from Brazil.},
  author={L{\'i}via de Souza Ramos and Maria Helena Galdino Figueiredo-Carvalho and Leonardo Silva Barbedo and Mariangela Ziccardi and Alessandra Leal da Silva Chaves and Rosely Maria Zancop{\'e}-Oliveira and Marcia Ribeiro Pinto and Diana Bridon da graça Sgarbi and M Dornelas-Ribeiro and Marta Helena Branquinha and Andr{\'e} Luis Souza Santos},
  journal={The Journal of antimicrobial chemotherapy},
  year={2015},
  volume={70 1},
  pages={
          111-5
        }
}
OBJECTIVES The emerging fungal pathogens comprising the Candida haemulonii complex (Candida haemulonii, Candida haemulonii var. [] Key Method A susceptibility assay was performed using the broth microdilution method published by CLSI (M27-A3/M27-S3). RESULTS Based on biochemical tests, all Brazilian isolates were identified as C. haemulonii. After employing ITS sequencing, five isolates were identified as C. haemulonii, four as C. duobushaemulonii and three as C. haemulonii var. vulnera. All 12 clinical…

Figures from this paper

Identification and Antifungal Susceptibility Profiles of Candida haemulonii Species Complex Clinical Isolates from a Multicenter Study in China

TLDR
The results reinforce the need for MALDI-TOF MS and/or molecular differentiation of species within the C. haemulonii complex and the multiresistant antifungal susceptibility profile of these isolates represents a challenge to therapy.

The Threat Called Candida haemulonii Species Complex in Rio de Janeiro State, Brazil: Focus on Antifungal Resistance and Virulence Attributes

TLDR
The results reinforce the multidrug resistance profile of the C. haemulonii species complex, including Brazilian clinical isolates, as well as their ability to produce important virulence attributes such as biofilms and different classes of hydrolytic enzymes, hemolysins and siderophores, which typically present a strain-dependent profile.

Superficial candidosis by Candida duobushaemulonii: An emerging microorganism.

Susceptibility of the Candida haemulonii Complex to Echinocandins: Focus on Both Planktonic and Biofilm Life Styles and a Literature Review

TLDR
This is the first report of the anti-biofilm action of echinocandins against the multidrug-resistant opportunistic pathogens comprising the C. haemulonii complex, and unveils the therapeutic potential of these compounds.

Insights into the Multi-Azole Resistance Profile in Candida haemulonii Species Complex

TLDR
Data point out the relevance of drug efflux pumps in mediating azole resistance in the C. haemulonii complex, and mutations in ERG11p may contribute to this resistance profile.

Candida haemulonii Complex Species, Brazil, January 2010–March 2015

TLDR
The clinical and microbiological characteristics of patients from 5 hospitals in Sao Paulo, Brazil, whose cultures were positive for the C. haemulonii complex species are described and diabetes mellitus was found substantially more frequently among patients with C. duobushaemul onii.

Immunopathogenesis of Emerging Candida auris and Candida haemulonii Strains

TLDR
Both emerging Candida species were virulent in a zebrafish model of infection and could activate the inflammatory pathway, and this study serves as a stepping stone for further pathogenesis studies of these important emerging species.

First Genome Sequences of Two Multidrug-Resistant Candida haemulonii var. vulnera Isolates From Pediatric Patients With Candidemia

Candida haemulonii is a complex formed by C. haemulonii sensu stricto, C. haemulonii var. vulnera, and C. duobushaemulonii. Members of this complex are opportunistic pathogens closely related to C.

Candida duobushaemulonii: an emerging rare pathogenic yeast isolated from recurrent vulvovaginal candidiasis in Brazil

TLDR
The importance of accurate identification of the fungal agents by a reliable molecular technique in RVVC episodes besides the lower antifungal susceptibility profile of this rare pathogen C. duobushaemulonii to FLZ is emphasised.

Candida haemulonii sensu lato: Update of the Determination of Susceptibility Profile in Argentina and Literature Review

TLDR
This review summarizes the information available of Candida haemulonii sensu lato, and updates the in vitro susceptibility profile of the isolates of these species from Argentina, and reviews the current situation in other countries.
...

References

SHOWING 1-10 OF 21 REFERENCES

Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features.

  • Mina KimJong-Hee Shin D. Ryang
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2009
TLDR
Candida species that are closely related to C. haemulonii are emerging sources of infection in Korea and show variable patterns of susceptibility to amphotericin B and azole antifungal agents.

Detection of Amphotericin B Resistance in Candida haemulonii and Closely Related Species by Use of the Etest, Vitek-2 Yeast Susceptibility System, and CLSI and EUCAST Broth Microdilution Methods

TLDR
This study provides the first data on the efficacy of the Etest-MH and its excellent agreement with Vitek-2 for discriminating AMB-resistant fromAMB-susceptible isolates of these Candida species.

First report of a clinical isolate of Candida haemulonii in Brazil

TLDR
The present paper reports for the first time a case of fungemia caused by C. haemulonii in a tertiary hospital in the city of Sao Paulo, Brazil, which has not been identified in previous reports of candidemia from Brazil.

Reclassification of the Candida haemulonii Complex as Candida haemulonii (C. haemulonii Group I), C. duobushaemulonii sp. nov. (C. haemulonii Group II), and C. haemulonii var. vulnera var. nov.: Three Multiresistant Human Pathogenic Yeasts

TLDR
The new species and the new variety have a multiresistant antifungal profile, which includes high MICs of amphotericin B and cross-resistance to azole compounds and should be based on molecular methods, such as sequence analysis of ITS regions and matrix-assisted laser desorption ionization–time of flight mass spectrometry.

Candida pseudohaemulonii Sp. Nov., an Amphotericin B‐ and Azole‐Resistant Yeast Species, Isolated from the Blood of a Patient from Thailand

TLDR
The new species and C. haemulonii types I and II were resistant to amphotericin B and azole agents but were susceptible to a 1,3‐β‐D‐glucan synthetase inhibitor, micafungin, and 5‐flucytosine.

Catheter-related Candidemia Caused by Candida haemulonii in a Patient in Long-term Hospital Care

TLDR
An echinocandin such as caspofungin may be an appropriate empirical choice of antifungal agent for an invasive C. haemulonii infection.

A case of Candida haemulonii osteitis: clinical features, biochemical characteristics, and antifungal resistance profile.

TLDR
The first case of osteitis caused by Candida haemulonii in a young immunocompetent patient presented a history of severe peripheral vascular disease associated with a lack of hygienic conditions as the only risk factors for such an uncommon infection.

Non-albicans Candida species in blood stream infections in a tertiary care hospital at New Delhi, India

TLDR
The study demonstrates a shift to non-albicans Candida species causing fungaemia and the emergence of amphotericin B and azole resistant novel species, C. haemulonii, which may limit the use of these agents as a presumptive therapy for Candida blood stream infections (BSI).